Patients treated with XELJANZ/XELJANZ XR are at increased risk for developing serious infections that may lead to hospitalization or death. After a maximum of $15,000, you will be responsible for paying the remaining monthly out-of-pocket costs.This Card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.You must deduct the value of this card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.You are responsible for reporting use of the Card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the Card, as may be required. Caution should be used when administering XELJANZ XR to patients with pre-existing severe gastrointestinal narrowing. Support: +1-214-291-3990 | Sales: +1-800-201-0333 Privacy Policy You can also call customer service at 1-844-935-5269.You represent that you are the account holder for the mobile telephone number(s) that you provide to opt into the Program. The interval between live vaccinations and initiation of tofacitinib therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents. If your doctor has prescribed XELJANZ and you need help paying for it, XELSOURCE may be able to assist, depending on eligibility, terms and conditions. Active tuberculosis, which may present with pulmonary or extrapulmonary disease. XELJANZ/XELJANZ XR (tofacitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs). XELJANZ/XELJANZ XR should be used with caution in patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs).Angioedema and urticaria that may reflect drug hypersensitivity have been observed in patients receiving XELJANZ/XELJANZ XR and some events were serious. The most commonly reported adverse reactions during the first 3 months in controlled clinical trials in patients with rheumatoid arthritis RA with XELJANZ 5 mg twice daily and placebo, respectively, (occurring in greater than or equal to 2% of patients treated with XELJANZ with or without DMARDs) were upper respiratory tract infection, nasopharyngitis, diarrhea, headache, and hypertension. DOING SO WILL ONLY OPT YOU OUT OF THIS PROGRAM; you will remain opted in to any other Pfizer Inc text message program(s) into which you opted separately.To request more information or to obtain help, text HELP to 50336. In animal studies, tofacitinib at 6.3 times the maximum recommended dose of 10 mg twice daily demonstrated adverse embryo-fetal findings. Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.Patients are not eligible to use this card if they are enrolled in a state and federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).Patient must have private insurance. No license to or right in any such Content is granted to or conferred upon you. Contact XELSOURCE for details.By using the XELJANZ XR/XELJANZ Co-pay Savings Card (the "Card"), you acknowledge that you currently meet the eligibility criteria and will comply with the following terms and conditions.Patients are not eligible to use this card if they are enrolled in a state and federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).Patient must have private insurance. The user can then compose a message, add attachments and recipients like normal. You agree to review these SMS Terms and Conditions periodically to ensure that you are aware of any changes. NMSCs have been reported in patients treated with XELJANZ. WE AND SONEXUS DO NOT WARRANT THAT THE WEBSITE OR ANY MATERIALS, INFORMATION, SOFTWARE, PRODUCTS, OR SERVICES INCLUDED IN OR AVAILABLE THROUGH THE WEBSITE ARE ACCURATE, RELIABLE, ERROR-FREE, OR UNINTERRUPTED; THAT THE WEBSITE WILL BE AVAILABLE AT ANY PARTICULAR TIME OR LOCATION; THAT ANY DEFECTS OR ERRORS WILL BE CORRECTED; THAT THE WEBSITE OR THE SERVER THAT MAKES IT AVAILABLE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS; OR THAT THE WEBSITE OR ANY MATERIALS, INFORMATION, SOFTWARE, PRODUCTS, OR SERVICES INCLUDED IN OR AVAILABLE THROUGH THE WEBSITE WILL OTHERWISE MEET YOUR NEEDS OR EXPECTATIONS. XELJANZ/XELJANZ XR (tofacitinib) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or who are intolerant to TNF blockers.